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Aim of the study: To evaluate the risk 
of endometrial malignancy in post-
menopausal women with abnormal 
uterine bleeding (AUB) with endome-
trial thickness ≤ 4 mm.
Material and methods: Histological 
assessment of endometrial samples 
obtained via hysteroscopy or curet-
tage was performed in 57 women. 
Results: Women with premalignan-
cy or malignancy (24.6%) had higher 
endometrial thickness (by 9.7%, p = 
0.01) compared to women with be-
nign condition. Out of 12 women with 
atypical hyperplasia (21.1%), 5 wom-
en (8.8%) were diagnosed with simple 
and 7 women (12.3%) had complex 
hyperplasia, whereas 2 (3.5%) were 
diagnosed with malignancy.
Conclusions: Postmenopausal wom-
en with AUB and endometrial echo 
≤ 4 mm are less likely to have a ma-
lignant condition. However, the role 
of histological evaluation cannot be 
undermined, especially in women at 
high risk of endometrial cancer, and 
routine endometrial biopsy should be 
considered. We recommend a change 
in the cut-off to 2 mm in routine 
practice.
Key words: endometrial thickness, 
endometrial cancer, postmenopausal 
bleeding, abnormal uterine bleeding.
Contemp Oncol (Pozn) 2019; 23 (1): 43–46
DOI: https://doi.org/10.5114/wo.2019.83816
Original paper
The thin red line – postmenopausal 
abnormal uterine bleeding with 
endometrial thickness less than 4 mm
Magdalena Piróg, Olga Kacalska-Janssen, Tomasz Bereza, Robert Jach
Department of Gynecological Endocrinology, Jagiellonian University Medical College, 
Krakow, Poland
Introduction
Postmenopausal abnormal uterine bleeding (AUB), which is present in 5% 
of women, is defined as pathological bleeding from the genital tract that oc-
curs at least 12 months after a woman’s last menstruation [1]. Vaginal bleed-
ing may be the presenting sign of endometrial cancer, which is the most 
common malignancy of the female reproductive tract in developed countries 
[2]. The incidence of postmenopausal AUB decreases with age, while the 
possibility of cancer as the underlying cause escalates from approximately 
1% at the age of 50 to 25% in women aged 80 years [3]. Factors increasing 
the risk of malignancy in endometrial tissue include obesity, diabetes mel-
litus, arterial hypertension, nulliparity and unopposed estrogen therapy [4].
Dilation and curettage, an endometrial aspiration (office biopsy) and hys-
teroscopy (hysteroscopic guided biopsy) are used to obtain a tissue sample 
for the diagnosis and treatment of endometrial pathologies. However, endo-
metrial thickness measurement using transvaginal ultrasound is a common 
screening method for triaging AUB in postmenopausal women [2]. In case 
of endometrial thickness > 4 mm endometrial sampling is indicated to ex-
clude malignancy. In women with endometrial echo ≤ 4 mm the probability 
of endometrial malignancy is considered to be low; therefore refraining from 
endometrial biopsy or curettage is sometimes considered justified [5].
The aim of this study was to investigate the risk of developing endome-
trial malignancy in women with postmenopausal bleeding with endometrial 
thickness ≤ 4 mm.
Material and methods
The retrospective study included 57 Caucasian women presenting with 
postmenopausal bleeding at the Gynecological Endocrinology Department, 
Jagiellonian University Medical College, from January 2014 to December 
2016. Postmenopausal bleeding was defined as one-time or recurrent vag-
inal bleeding after at least 12 months of amenorrhea. Only women with 
endometrial thickness ≤ 4 mm were included in the analysis. Women with 
self-reported history of breast cancer with or without therapy with tamox-
ifen (n = 1) and use of anticoagulants (n = 3) were excluded. The diagnos-
tic work-up consisted of a double-layer measurement of the endometrium 
using transvaginal ultrasound and a cervical smear. The endometrial thick-
ness was measured at its thickest point from the anterior to the posteri-
or in the sagittal plane of the uterus. An endometrial sample was obtained 
via hysteroscopic biopsy or dilatation and curettage. Hysteroscopic biopsy 
was more often performed among women with suspected polyps as well as 
among women with contraindications to general analgesia. Histological as-
sessment was performed by the pathologists from the Department of Patho- 
morphology, Jagiellonian University Medical College. 
Normal proliferative and atrophic endometrium as well as endometrial 
polyps were classified as benign. Endometrial hyperplasia without atypia was 
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considered as without the need for further followup, de-
spite the slightly increased risk of endometrial cancer. Both 
simple and complex atypical hyperplasia were classified as 
premalignant conditions. Hysterectomy was proposed to 
women with atypical hyperplasia and endometrial cancer.
Body mass index (BMI) was calculated by dividing 
weight in kilograms by square of height in meters. Infor-
mation about concomitant diseases such as diabetes mel-
litus, arterial hypertension, hypercholesterolemia, as well 
as number of pregnancies, was obtained during a medical 
interview. Smoking was specified as being a current smok-
er. Hormone therapy (HT) users were defined as taking HT 
currently or in the perimenopausal period.
The Ethics Committee at Jagiellonian University Medical 
College approved the study, and participants provided in-
formed consent in accordance with the Declaration of Helsinki.
Statistical analysis 
Data were expressed as mean ± standard deviation or 
median (interquartile range) unless otherwise stated. The 
Kolmogorov-Smirnov test was used to assess conformity 
with a normal distribution. 
A 2-sided p-value of less than 0.05 was considered sta-
tistically significant. Statistical analyses were performed 
with Statistica 12 (StatSoft, Tulsa, OK, USA).
Results
The final analysis included 57 postmenopausal women 
aged from 42 to 69 years. 
The characteristics of the studied group are shown in Ta-
ble 1. Both groups with benign and malignant (or premalig-
nant) histologic results were similar regarding demographic 
variables. Forty-three women (75.4%) had their last men-
struation between the ages of 45 and 55. Only 13 women 
(22.8%) were diagnosed with obesity (BMI > 30 kg/m2) (data 
not shown). 
The two groups were similar regarding incidence of 
diabetes mellitus, arterial hypertension, hypercholesterol-
emia, smoking or use of HT (Table 1). All the participants 
had at least 1 child (data not shown).
Dilatation and curettage (73.7%) or hysteroscopy (26.3%) 
were performed to obtain endometrial samples. (Fig. 1). On 
histopathology, the majority of women (75.4%) had benign 
results, either normal proliferative and atrophic endome-
trium (56.1%) or hyperplastic endometrium without atypia 
(19.3%). Endometrial hyperplasia with atypia was detected 
in 12 (21.1%) women. Two women (3.5%) were diagnosed 
with endometrial malignancy; their ages were 60 and 54 
years, and they were diagnosed with clear cell adenocarci-
noma and uterine sarcoma, respectively. 
We also evaluated the number of patients according to 
histopathology and endometrial thickness in transvaginal 
ultrasonography (Table 2). As expected, the largest num-
ber of women with abnormal histology were in the group 
with the widest endometrium (by 9.7%) and had a mean 
endometrium thickness of 3.5 mm (data not shown). None 
of the participants from this group had endometrium 
thickness less than 2 mm. No similar changes were found 
in the benign histopathology group.
All women with both endometrial atypical hyperplasia 
and malignancy were treated with simple hysterectomy and 
bilateral oophorectomy. The final diagnosis of the hysterec-
tomy specimen performed among 12 women with atypical 
endometrial hyperplasia revealed that only 1 woman (8.3%) 
Table 1. Baseline characteristics of postmenopausal women with abnormal uterine bleeding
Characteristics Total
(n = 57)
Benign condition 
(n = 43)
Premalignancy or malignancy
(n = 14)
p
Age, years 56.6 ±6.6 55.8 ±6.9 57.1 ±5.5 0.77
BMI, kg/m2 25.3 (23.5–29.4) 24.6 (23.5–27.7) 26.0 (22.9–33.0) 0.47
Age of the last menstruation, years 51.1 ±4.3 50.5 ±4.5 52.9 ±2.9 0.48
Endometrial thickness, mm 3.2 ±0.6 3.1 ±0.6 3.4 ±0.4 0.01
Diabetes mellitus, n (%) 10 (17.5) 7 (16.3) 3 (21.4) 0.69
Arterial hypertension, n (%) 29 (50.9) 21 (48.8) 8 (57.1) 0.43
Smoking, n (%) 4 (7.0) 4 (9.3) 0 0.06
Hypercholesterolemia, n (%) 10 (17.5) 8 (18.6) 2 (14.3) 0.71
Hormone therapy, (%) 8 (14.0) 6 (14.0) 2 (14.3) 0.98
Fig. 1. Study flow diagram
First episode of 
postmenopausal 
bleeding with  
endometrial  
thickness less  
than 4 mm (n = 57)
Dilatation and 
curettage (n = 42) / 
hysteroscopy (n = 15) 
Histopathological 
assessment  
(n = 57) 
Benign condition 
(n = 43) 
Normal proliferative, 
atrophic endome-
trium, endometrial 
polyps (n = 32)
Endometrial 
hyperplasia without 
atypia (n = 11)
Premalignant condi-
tion or malignancy  
(n = 14)
Simple atypical 
hyperplasia  
(n = 5)
Complex atypical 
hyperplasia  
(n = 7)
Malignancy 
(n = 2)
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had endometrial cancer, which accounted for 10% of wom-
en with atypical hyperplasia with endometrial thickness 
between 3.1 and 4.0 mm (Table 3). The assessment in the 
hysterectomy material for clear cell carcinoma showed fo-
cal extension and the staging was Ib (FIGO grade 1). Histo-
pathological evaluation of uterine sarcoma demonstrated 
low-grade endometrial stromal sarcoma (FIGO IA).
Discussion 
Based on histology and clinical outcomes, endometrial 
cancers have been divided into two types. Type I tumors are 
associated with unopposed estrogen stimulation, and are 
often preceded by endometrial hyperplasia, whereas type II 
tumors are predominantly serous carcinomas and are com-
monly described as estrogen independent, arising in atrophic 
endometrium and deriving from intraepithelial carcinoma, 
a precancerous lesion [6]. In our study more than 20% of 
women were diagnosed with atypical hyperplastic endome-
trium, which is a precursor of type I endometrial cancer.
At present, transvaginal ultrasonography is the initial 
imaging procedure of choice for evaluating AUB in post-
menopausal women [7]. The possibility of abnormal (pre-
malignant or malignant) pathology is very limited in wom-
en with endometrial thickness less than 5 mm [8, 9].
The finding that 24.6% of women in the whole group 
had an abnormal histological diagnosis strongly indicates 
that an endometrial thickness ≤ 4 mm cannot be ignored 
and, where possible, a histological diagnosis must be 
sought. Our results confirm that endometrial cancers can 
indeed occur despite reassuring appearances of the endo-
metrium on an ultrasound scan. Büyük et al. also detected 
endometrial malignancies in women with an endometrial 
stripe as thin as 3 mm [10]. However, a meta-analysis of 
35 published studies showed that in 5 892 women with 
postmenopausal bleeding who had endometrial thick-
ness of 5 mm or more 95% of all endometrial malignan-
cies were identified, whereas in women with endometrial 
thickness less than 4 mm cancer was diagnosed in only 1% 
[11, 12]. Karlsson et al. reported that the risk of finding en-
dometrial pathology in women with endometrial thickness 
≤ 4 mm is 5.5% [13]. Moreover, Goldstein indicated that in 
women with postmenopausal bleeding, biopsy is not re-
quired when endometrial thickness is ≤ 4 mm [14]. Clark 
et al. found a strategy with TVS as the screening test with 
a cut-off of 4 mm followed by endometrial sampling being 
the most effective [15]. Ferrazzi et al. in a multicenter study 
of 930 postmenopausal women with AUB found 2 cases 
of endometrial cancer when endometrial thickness was 
≤ 4 mm and 4 participants with a malignant condition when 
endometrial thickness was ≤ 5 mm [16]. Gull et al. in two 
studies where women with postmenopausal AUB and the 
endometrial echo ≤ 4 mm were included confirmed only 1 
(0.6%) endometrial cancer in the first study (163 women 
involved), whereas no cases of malignant condition were 
found in the second study (394 women screened) [17, 18]. 
In another study where 97 women with postmenopausal 
AUB were recruited, no malignancies were confirmed with 
narrow endometrium ≤ 5 mm [19]. Interestingly, none of 
the above studies evaluated the correlation between the 
risk factors of endometrial cancer and endometrial thick-
ness. Based on the American College of Obstetricians and 
Gynecologists (ACOG) Committee Opinion, endometrial 
sampling is not required in women with postmenopausal 
AUB with an endometrial thickness of 4 mm or less be-
cause of a very low risk of uterine malignancy in these 
patients [20]. However, this committee also stated that 
when bleeding persists despite negative initial evaluation, 
additional assessment is indicated. Nevertheless, in our 
study we decided to perform histological examination of 
endometrial tissue despite the lack of obvious features of 
malignancy in transvaginal ultrasonography examination.
The main purpose of endometrial sampling is to exclude 
endometrial cancer. The accuracy of curettage compared 
to both hysteroscopy and Pipelle endometrial biopsy in 
differentiation between benign and malignant condition is 
uncertain. Endometrial biopsy is a less invasive procedure 
and it can be performed in the office. Nevertheless, it may 
not give a final diagnosis, especially when an insufficient 
amount of tissue is collected, which is present in women 
with endometrial thickness ≤ 4 mm [21]. That is why, in 
our study, we did not use that procedure to identify the 
cause of postmenopausal AUB. However, both curettage 
and Pipelle sampling have been reported to yield equal 
rates of cancer detection in patients with abnormal uter-
ine bleeding [22]. Hysteroscopy is better when imaging of 
the uterine cavity is required in the case of diagnosis of 
Table 2. Histopathological assessment of endometrial samples obtained via hysteroscopy or curettage in postmenopausal women with 
abnormal uterine bleeding
Histopathology Endometrial thickness (mm)
≤ 1.0 1.1–2.0 2.1–3.0 3.1–4.0
Normal proliferative, atrophic endometrium, endometrial polyps 0 1 13 18
Endometrial hyperplasia without atypia 0 2 2 7
Atypical hyperplasia 0 0 2 10
Malignancy 0 0 0 2
Table 3. Histopathological assessment of endometrium after hyster-
ectomy due to endometrial atypical hyperplasia in postmenopausal 
women with abnormal uterine bleeding
Endometrial thickness 
(mm)
Histopathological assessment
Atypical 
hyperplasia (n)
Endometrial cancer 
(n)
2.1–3.0 2 0
3.1–4.0 9 1
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focal lesions and it allows removal of polyps at the time 
of diagnosis. However, not all premalignant lesions can be 
visualized by hysteroscopy [23].
The article has several limitations. The population of 
women with postmenopausal AUB and narrow endometri-
um was limited. The first possible cause is that women with 
endometrial thickness ≤ 4 mm and postmenopausal abnor-
mal uterine bleeding do not undergo histopathological as-
sessment of endometrial sampling obtained during curet-
tage or hysteroscopy until the endometrial echo increases 
in size. The next possible cause of the limited population in 
this study is histopathological assessment of endometrial 
sampling obtained via Pipelle endometrial biopsy outside 
the hospital and lack of access to these results.
Finally, we did not follow the women with normal his-
topathologic results to assess the possible cause of AUB.
Conclusions
In conclusion, this study found that women with endo-
metrial echo ≤ 4 mm are less likely to be associated with 
a malignant condition. However, the role of histopatholog-
ical evaluation in postmenopausal women suffering from 
AUB with endometrial thickness ≤ 4 mm cannot be under-
mined, especially in patients at high risk of endometrial 
cancer. Nevertheless, considering the rising incidence of 
endometrial cancer, more research on this subject is need-
ed, using larger cohorts of women with postmenopausal 
AUB with thickened endometrium on transvaginal ultra-
sonography to evaluate the effectiveness and diagnostic 
accuracy of endometrial sampling. Therefore, we recom-
mend a change in the cut-off to 2 mm in routine practice.
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